A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT06649045
StatusCompleted
PhasePhase 3
SponsorEli Lilly and Company
Enrollment712 participants
DesignInterventional, Randomized, Parallel, Masking: Double
ConditionsOSA; Overweight or Obesity
InterventionsOrforglipron; Placebo
StartOct 22, 2024
Primary completionJul 21, 2026
Study completionJul 30, 2026
Results postedNot yet
Registry last updatedSep 14, 2026

Compounds on this site that cite this trial

What the registry says the trial is about

Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Change from Baseline in Apnea-Hypopnea Index (AHI)Baseline to Week 52

7 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 16, 2026. See the trial changes feed for what has changed recently.

Share thisFacebookXEmail